Integrative analysis of the PSMA family identifies PSMA6 as an adverse prognostic biomarker promoting bladder cancer cell proliferation
International Journal of Medical Sciences · 2026
DOI: 10.7150/ijms.119034 ↗At a glance
Journal article in International Journal of Medical Sciences, 2026. Written by Zhengnan Huang and 5 co-authors. Institution: Department of Urology, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200011, China. Major MEDLINE topics: Biomarkers, Tumor, Urinary Bladder Neoplasms, Proteasome Endopeptidase Complex. The full text is freely available in PubMed Central.
Abstract (original language)
Background
Proteasome subunit alpha members (PSMAs) are reported to be involved in diverse biological processes, and mounting evidence indicates that PSMAs have been implicated in the carcinogenesis of various malignancies. Nevertheless, there is a scarcity of reports on the expression, prognostic significance, and potential functions of the PSMA family in bladder cancer (BLCA).
Methods
We utilized the TCGA, GEO, TIMER, UALCAN, and HPA databases to evaluate the expression of PSMAs in BLCA. Survival analyses were performed using Kaplan-Meier methods. The validation of PSMA6 dysregulation in human BLCA samples encompassed western blotting and immunohistochemistry. For the enrichment of biological processes, we applied Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and Gene Set Enrichment Analyses (GSEA). Subsequent analyses involved the exploration of correlations between gene expression and Immune-related effects. In-depth investigations into the role of PSMA6 in BLCA were conducted through both in vitro and in vivo experiments.
Results
We demonstrated that PSMA6 was upregulated among PSMAs in BLCA, and overexpression of PSMA6 was associated with unfavorable prognosis and tumor malignancy. Enrichment analyses disclosed the involvement of PSMA6 in immune-related activities within the tumor microenvironment. Furthermore, the expression of PSMA6 was closely correlated with tumor-infiltrating immune cells (TICs) and immune checkpoints (ICPs). Besides, we also revealed that BLCA patients with high PSMA6 expression would have better immunotherapy response. Functional studies demonstrated that PSMA6 knockdown suppressed BLCA cell proliferation in vitro and in vivo.
Conclusions
Our findings suggested that PSMA6 might function as an unfavorable prognostic biomarker, fostering BLCA cell proliferation, while also potentially serving as a predictive indicator for the efficacy of immunotherapy in BLCA patients.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Urology, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200011, China.
- Department of Urology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai 200072, China.
- Urologic Cancer Institute, School of Medicine, Tongji University, Shanghai 200092, China.
- Tongji University Cancer Center, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai 200072, China.
- Shanghai Key Lab of Cell Engineering, Shanghai 200433, China.
- Department of Stem Cells and Regenerative Medicine, Translational Medicine Research Center, Naval Medical University, Shanghai 200433, China.
Cite
APA
Huang, Z., Cao, X., Yan, Y., Li, H., Shen, B., & Wang, T. (2026). Integrative analysis of the PSMA family identifies PSMA6 as an adverse prognostic biomarker promoting bladder cancer cell proliferation. International Journal of Medical Sciences. https://doi.org/10.7150/ijms.119034
Vancouver
Huang Z, Cao X, Yan Y, Li H, Shen B, Wang T. Integrative analysis of the PSMA family identifies PSMA6 as an adverse prognostic biomarker promoting bladder cancer cell proliferation. International Journal of Medical Sciences. 2026. doi:10.7150/ijms.119034
BibTeX
@article{Huang2026,
author = {Huang, Zhengnan and Cao, Xiangqian and Yan, Yilin and Li, Huaxing and Shen, Bing and Wang, Tengjiao},
title = {Integrative analysis of the PSMA family identifies PSMA6 as an adverse prognostic biomarker promoting bladder cancer cell proliferation},
journal = {International Journal of Medical Sciences},
year = {2026},
doi = {10.7150/ijms.119034}
}
EUVIMED